Our Company

HCW Biologics Inc. (Nasdaq: HCWB) is a commercial-and-clinical stage biopharmaceutical company developing first-in-class immunotherapies to revolutionize the treatments for autoimmune diseases, cancer and senescence-associated dysplasia.

By leveraging our extensive immunology expertise, we have developed fusion immunotherapeutics representing a new class of drugs that we believe have the potential to fundamentally change the treatments for autoimmune diseases, cancer, senescence-associated dysplasia, and many other diseases promoted by chronic inflammation — and in doing so, improve patients’ quality of life and possibly extend longevity.

HCW Biologics has an experienced team led by Dr. Hing C. Wong, our Founder and CEO, who discovered and developed the immunotherapeutic Anktiva^® (also known as ALT-803, an IL-15 receptor agonist) through pivotal trials. This blockbuster immunotherapeutic treatment for cancer was sold to ImmunityBio, Inc. in 2017 in a $1.0 billion acquisition. In April 2024, Anktiva^® was approved by the U.S. Food and Drug Administration for its first indication, the treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.

The Company utilized its proprietary drug discovery and development platforms to create novel fusion immunotherapeutics, including multi-specific cytokines, targeted second-generation immune checkpoint inhibitors, and immune-cell engagers, which have the capabilities to rebalance immune cells to reestablish immune tolerance or rejuvenate subsets of immune cells that specifically target cancerous and infected cells, and accumulated, nonfunctional senescent cells. Our specialty is to develop treatments administered by subcutaneous injection, with an eye toward cost containment and cost savings when we reach the commercialization stage as well as quality-of-life for the patient.

Among our lead product candidates, we currently have two proprietary fusion immunotherapeutics that have reached the commercial stage for supporting cell-based therapies for cancer and infectious diseases, and one fusion immunotherapeutic being evaluated in a clinical trial for an autoimmune disease. Advancing our lead product candidates in clinical and commercial stage may be accomplished with Company-sponsored programs or with a corporate partner. Business development transactions are considered a key aspect of our financing strategy. We continually assess our programs to determine the optimal path to successfully complete clinical development and launch commercialization.